报告时间：2022年12月29日（星期四）09:00-11:00
报告地点：线上腾讯会议：327-540-242
报告人：ZHU YINGHUAI教授
工作单位：东阳光药业研究院
举办单位：bat365官网登录入口，先进催化与反应工程安徽省重点实验室，可控化学与材料化工安徽省重点实验室，先进功能材料与器件安徽省重点实验室
报告简介：
Boron neutron capture therapy (BNCT) has attracted earnest efforts and interest from both academia and the pharmaceutical industry in recent years due to its high potential in clinical applications. Following the latest development and popularization of neutron sources in China, BNCT is expected to play more important roles in cancer treatment in China. The FDA approved compounds, 4-borono-L-phenylalanine (BPA) and sodium borocaptate (BSH) (Na2B12H11SH), are currently in clinical trials but neither has fully achieved the tumor selectivity required for BNCT treatment, i.e., with less accumulation in normal tissues and/or blood. The development of a boron drug that meets all the requirements of BNCT thus remains a challenge. This lecture summarizes the syntheses of boron analogues of a-amino acid-based agents and their unique efficacy in anti-tumor and anti-rheumatoid arthritis through boron neutron capture therapy.
报告人简介：
Dr. Yinghuai Zhu received his PhD degree from Nankai University in 1997 and then stayed on as an assistant/associate professor while also working as a postdoctoral fellow in Northern Illinois University. In 2002, he joined the Institute of Chemical and Engineering Sciences (ICES), A*STAR, Singapore as a senior research fellow. After 14 years there, followed by a brief stint as a visiting scientist back at Northern Illinois University, he joined the Macau University of Science and Technology. Since 2020, he has been with Sunshine Lake Pharma as an expert in new drug R&D. His research interests include new generation anti-cancer and anti-infective drugs such as in boron neutron capture therapy, and new nanocomposites as high efficiency catalysts in green chemistry and energy research. He has published more than 85 papers with a total citation count of more than 3300, twelve book chapters, and he holds three patents.
